BioStem Technologies Appoints Brandon Poe as Chief Financial Officer
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived advanced wound care products, has appointed Brandon Poe as its new Chief Financial Officer. Poe, who has served on BioStem's Board since 2022, brings over 25 years of healthcare and life sciences experience, including senior finance roles at Midi Health, Jumpcode Genomics, and Illumina.
The appointment comes at a strategic time as BioStem pursues market expansion and Nasdaq uplisting plans. The former CFO, Michael Fortunato, will transition to the role of Chief Accounting Officer. Poe's extensive background in capital markets and operational excellence, combined with his familiarity with BioStem's business, positions him to support the company's growth initiatives and BioREtain® platform development.
BioStem Technologies (OTC: BSEM), azienda MedTech specializzata in prodotti avanzati per la cura delle ferite derivati dalla placenta, ha nominato Brandon Poe nuovo Chief Financial Officer. Poe, membro del consiglio di BioStem dal 2022, vanta oltre 25 anni di esperienza nei settori sanitario e delle scienze della vita, con ruoli finanziari dirigenziali presso Midi Health, Jumpcode Genomics e Illumina.
La nomina arriva in un momento strategico, mentre BioStem punta a espansione di mercato e all'ammissione al Nasdaq. L'ex CFO, Michael Fortunato, assumerà il ruolo di Chief Accounting Officer. L'ampio background di Poe nei mercati dei capitali e nell'eccellenza operativa, insieme alla sua familiarità con il business di BioStem, lo rende adatto a sostenere le iniziative di crescita dell'azienda e lo sviluppo della piattaforma BioREtain®.
BioStem Technologies (OTC: BSEM), una empresa MedTech especializada en productos avanzados para el cuidado de heridas derivados de la placenta, ha nombrado a Brandon Poe como su nuevo Chief Financial Officer. Poe, que forma parte del consejo de BioStem desde 2022, aporta más de 25 años de experiencia en salud y ciencias de la vida, incluyendo cargos financieros sénior en Midi Health, Jumpcode Genomics e Illumina.
El nombramiento se produce en un momento estratégico, mientras BioStem busca expandirse en el mercado y cotizar en Nasdaq. El anterior CFO, Michael Fortunato, pasará a desempeñar el puesto de Chief Accounting Officer. La amplia experiencia de Poe en mercados de capital y excelencia operativa, junto con su conocimiento del negocio de BioStem, le permite apoyar las iniciativas de crecimiento de la compañía y el desarrollo de la plataforma BioREtain®.
BioStem Technologies (OTC: BSEM), 태반 유래의 첨단 상처 치료 제품을 전문으로 하는 MedTech 기업이 Brandon Poe를 신임 최고재무책임자(CFO)로 임명했습니다. Poe는 2022년부터 BioStem 이사회에서 활동해 왔으며, Midi Health, Jumpcode Genomics, Illumina 등에서의 고위 재무 역할을 포함해 25년 이상의 헬스케어 및 생명과학 경험을 보유하고 있습니다.
이번 임명은 BioStem이 시장 확장 및 나스닥 상장 계획
BioStem Technologies (OTC: BSEM), société MedTech spécialisée dans les produits avancés de cicatrisation dérivés du placenta, a nommé Brandon Poe comme nouveau Chief Financial Officer. Poe, membre du conseil d'administration de BioStem depuis 2022, apporte plus de 25 ans d'expérience dans la santé et les sciences de la vie, ayant occupé des postes financiers de direction chez Midi Health, Jumpcode Genomics et Illumina.
Cette nomination intervient à un moment stratégique, alors que BioStem poursuit des projets d'extension de marché et d'inscription au Nasdaq. L'ancien CFO, Michael Fortunato, passera au poste de Chief Accounting Officer. L'expérience approfondie de Poe sur les marchés de capitaux et en excellence opérationnelle, combinée à sa connaissance de l'activité de BioStem, le place en bonne position pour soutenir les initiatives de croissance de la société et le développement de la plateforme BioREtain®.
BioStem Technologies (OTC: BSEM), ein MedTech-Unternehmen, das sich auf plazentabasiertes Advanced Wound Care spezialisiert hat, hat Brandon Poe zum neuen Chief Financial Officer ernannt. Poe, der seit 2022 im Vorstand von BioStem sitzt, bringt mehr als 25 Jahre Erfahrung im Gesundheits- und Life-Sciences-Bereich mit, darunter leitende Finanzpositionen bei Midi Health, Jumpcode Genomics und Illumina.
Die Ernennung erfolgt zu einem strategischen Zeitpunkt, da BioStem eine Markterweiterung und einen Nasdaq-Listing anstrebt. Der bisherige CFO, Michael Fortunato, wechselt in die Rolle des Chief Accounting Officer. Poes umfassender Hintergrund in den Kapitalmärkten und in operativer Exzellenz sowie seine Vertrautheit mit BioStems Geschäftsfeld versetzen ihn in die Lage, die Wachstumsinitiativen des Unternehmens und die Entwicklung der BioREtain®-Plattform zu unterstützen.
- Appointment of experienced CFO with 25+ years in healthcare and life sciences
- New CFO's prior board experience provides deep understanding of company operations
- Strategic move supporting Nasdaq uplisting initiative
- Retention of former CFO as Chief Accounting Officer maintains continuity
- None.
Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem’s financial team
POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem’s Board of Directors since 2022. Michael Fortunato, the Company’s prior CFO, has assumed the role of Chief Accounting Officer.
“I’m excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem,” said Jason Matuszewski, Chairman and CEO. “Brandon brings proven financial leadership across life sciences, medical devices, and healthcare services, with deep expertise in capital markets, strategic planning, and operational excellence. His contributions as a Board member have already proven invaluable, and his intimate knowledge of our business will be a powerful advantage as we expand into new markets, advance our Nasdaq uplisting, and deliver on our long-term growth ambitions.”
Mr. Poe is an accomplished finance leader with more than 25 years of experience across the healthcare and life sciences sectors. He most recently served as Chief Financial Officer of Midi Health, Inc., a privately held digital women’s healthcare company. Prior to that, he was Chief Financial Officer of Jumpcode Genomics, Inc., a privately held life sciences company. Earlier in his career, Mr. Poe spent eight years at Illumina, Inc. (NASDAQ: ILMN), a publicly traded life sciences company, where he served in multiple senior finance roles, most recently as Vice President of Finance for Product Development, Research and Global Operations. Mr. Poe holds an undergraduate degree from Bucknell University and an MBA from the University of Chicago’s Booth School of Business.
“BioStem is a recognized leader in innovative wound care technologies, and I am thrilled to serve as CFO at this pivotal stage in the Company’s evolution,” said Brandon Poe, Chief Financial Officer of BioStem. “With the proven strength of BioStem’s BioREtain® platform, scalable manufacturing capabilities, and expanding clinical evidence, we are well-positioned to accelerate growth and broaden our market presence. I look forward to working alongside this talented team to execute on our strategy and drive value for our shareholders.”
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain®processing method. BioREtain®has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow the Company on X and LinkedIn.
Contact BioStem Technologies, Inc.:
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Adam Holdsworth
BioStem Director of Investor Relations
E-Mail: adam@biostemtech.com
Phone: 917-497-9287
Or
Gilmartin Group
Philip Trip Taylor, Principal
E-Mail: philip@gilmartinir.com
Phone: 415-937-5406
Note Regarding Forward-Looking Statements:
Except for statements of historical fact, this press release also contains forward-looking statements. These forward-looking statements relate to expectations or forecasts of future events, including with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements in this press release include, among other things, statements regarding the Company’s: growth strategy, including entering new product markets ; and expectations regarding the Company’s plans to list its stock on Nasdaq. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from the expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: the risk that the Company may be unable to list its stock on Nasdaq or maintain compliance with Nasdaq’s continued listing standards; the impact of any changes to the accounting treatment of the Company’s revenue and expenses; the risk of receiving additional comments from the SEC; the competition that the Company faces, which could adversely affect its business, results of operations and financial condition; the risk of rapid technological change, which could cause the Company’s products to become obsolete or cause the Company to become unable to effectively compete; the risk that the Company is unable to successfully market its products to the end users of such products; the risk that the Company may be unable to raise funds to expand its business; changes in applicable laws or regulations; and the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
Who is the new CFO of BioStem Technologies (BSEM)?
What is Brandon Poe's experience before joining BioStem as CFO?
What are BioStem Technologies' current strategic initiatives?
What happened to BioStem's previous CFO?
What is BioStem Technologies' main business focus?
